Cann Group

Cann Group is a leading biopharma company founded in 2017 and headquartered in Australia. The company's slogan, "Our business is science, our product is quality of life," reflects its commitment to the development and supply of high-quality medicinal cannabis products. Cann Group's focus on breeding, cultivating, manufacturing, and supplying medicinal cannabis has positioned it as a prominent player in the industry.

The company has strategically established research, cultivation, and GMP manufacturing facilities in Bundoora, northern Melbourne, as well as a large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. This infrastructure supports Cann Group's objective to provide high-quality, safe medicinal cannabis for various diseases and medical conditions. Notably, the company's brand portfolio includes the proprietary Satipharm delivery system for cannabinoids, a significant differentiator in the market.

Furthermore, Cann Group's Botanitech brand offers a diverse, affordable, and high-quality product range, catering to an expanding market. The company's new, state-of-the-art facility in regional Victoria has commenced operations and holds the capacity to produce 12,500kg of high-quality flower per year. With substantial R&D collaborations and exclusive, proprietary lines of high-yielding cultivars, Cann Group is poised to meet growing demand and advance its position in the medicinal cannabis sector.

As Cann Group remains committed to the future of high-quality, low-cost cannabis medicines, it strives to establish itself as a reliable and trusted industry participant, setting the stage for potential future investments and collaborations.